C4 Therapeutics (CCCC) Net Income (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Net Income of -$27.4 million for Q1 2026, down 4.27% year-over-year from -$28.7 million in Q1 2025, and down 34.77% quarter-over-quarter from -$20.4 million in Q4 2025.
C4 Therapeutics (CCCC) Net Income (2019 - 2026) Analysis & Trends
C4 Therapeutics' Net Income history runs 8 years deep, the most recent figure standing at -$27.4 million for Q1 2026.
- In Q1 2026, Net Income fell 4.27% year-over-year to -$27.4 million; the TTM figure through Mar 2026 stood at -$106.0 million (down 2.63% YoY), while the FY2025 annual figure was -$105.0 million, changed 0.31% from the prior year.
- Net Income for Q1 2026 stood at -$27.4 million, down from -$20.4 million in the prior quarter.
- The five-year high for Net Income was -$17.7 million in Q2 2024, with the low at -$128.7 million in Q2 2022.
- The 5-year median for Net Income is -$31.6 million (2022), against an average of -$35.3 million.
- The sharpest annual moves came in 2022 and 2023: Net Income tumbled 469.84% in 2022, then jumped 72.08% in 2023.
- C4 Therapeutics' Net Income stood at -$37.2 million in 2022, then grew by 6.53% to -$34.8 million in 2023, then grew by 0.53% to -$34.6 million in 2024, then surged by 41.1% to -$20.4 million in 2025, then tumbled by 34.77% to -$27.4 million in 2026.
- Business Quant data shows CCCC's Net Income at -$27.4 million in Q1 2026, -$20.4 million in Q4 2025, and -$32.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | -24.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.08 Mn |
| Mar 31, 2026 | -27.45 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Sep 30, 2025 | -32.17 Mn |
| Jun 30, 2025 | -26.02 Mn |
| Mar 31, 2025 | -26.32 Mn |
| Dec 31, 2024 | -34.57 Mn |
| Sep 30, 2024 | -24.67 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Mar 31, 2024 | -28.36 Mn |
| Dec 31, 2023 | -34.76 Mn |
| Sep 30, 2023 | -27.04 Mn |
| Jun 30, 2023 | -35.92 Mn |
| Mar 31, 2023 | -34.78 Mn |
| Dec 31, 2022 | -37.19 Mn |
| Sep 30, 2022 | -31.96 Mn |
| Jun 30, 2022 | -128.67 Mn |
| Mar 31, 2022 | -31.62 Mn |
| Dec 31, 2021 | -15.66 Mn |
| Sep 30, 2021 | -24.68 Mn |